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Up to 60% of gastro-oesophageal junction (GEJ) adenocarcinomas show nuclear b-catenin expression, pointing to activated T-cell
factor (TCF)/b-catenin-driven gene transcription. We demonstrate in five human GEJ adenocarcinoma cell lines that nuclear b-
catenin expression indeed correlates with enhanced TCF-mediated transcription of a reporter gene. In several tumour types, TCF/b-
catenin activation is caused by mutations in either adenomatous polyposis coli (APC), b-catenin exon 3, AXIN1, AXIN2 or b-transducin
repeat-containing protein (b-TrCP). In GEJ adenocarcinomas, very few APC and b-catenin mutations have been found. Therefore, the
mechanism of Wnt pathway activation remains unclear. In the present study, we did not find AXIN1 gene mutations in 17 GEJ
tumours with nuclear b-catenin expression (without b-catenin exon 3 mutations). Six intragenic single nucleotide polymorphisms
(SNPs) were identified. One of these, the AXIN1 gene T1942C SNP, has a frequency of 21% but is only very recently described
despite numerous AXIN1 gene mutational studies. We provide evidence why this SNP was missed in single strand conformation
polymorphism analyses. The AXIN1 gene G2063A variation was previously described as a gene mutation but we demonstrate that
this is a polymorphism. With these six SNPs loss of heterozygosity (LOH) was found in 11 of 15 (73%) informative tumours. To
investigate a possible AXIN1 gene dosage effect in GEJ tumours expressing nuclear b-catenin, AXIN1 locus LOH was determined in
20 tumours expressing membranous and no nuclear b-catenin. LOH was found in 10 of 13 (77%) informative cases. AXIN1 protein
immunohistochemistry revealed cytoplasmic expression in all tumours irrespective of the presence of AXIN1 locus LOH. These data
indicate that nuclear b-catenin expression is indicative for activated Wnt signalling and that neither AXIN1 gene mutations nor AXIN1
locus LOH are involved in Wnt pathway activation in GEJ adenocarcinomas.
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The incidence of adenocarcinoma of the gastro-oesophageal
junction (GEJ), that is, distal oesophagus and gastric cardia, is
rising in the Western world (Blot et al, 1991; Powell and
McConkey, 1992; Botterweck et al, 2000). Patients with GEJ
adenocarcinoma have a poor prognosis with 5-year survival rates
of less than 25% (Tilanus et al, 1993). Despite the common
occurrence of this malignancy, relatively little is known about the
molecular mechanisms underlying the genesis and the progression
of these tumours.
Numerous studies focused on cell–cell adhesion in GEJ
adenocarcinomas since defective cell–cell adhesion is an impor-
tant feature in epithelial tumour initiation and progression
(Jankowski et al, 1997; Hirohashi, 1998; Nollet et al, 1999;
Wijnhoven et al, 2000a; Van Aken et al, 2001; Hajra and Fearon,
2002). Aberrant expression of components of the E-cadherin–
catenin complex, the prime mediator of epithelial cell–cell
adhesion, has been found frequently in GEJ adenocarcinomas. In
addition, E-cadherin–catenin complex aberrations appeared to
have prognostic value in these tumours (Jian et al, 1997;
Krishnadath et al, 1997; Bailey et al, 1998; Washington et al,
1998; Bian et al, 2000; Osterheld et al, 2002).
Recently, the E-cadherin–catenin complex component b-
catenin has been demonstrated to play a dual role in the
tumorigenic process (Korinek et al, 1997; Morin et al, 1997;
Resnik, 1997; Rubinfeld et al, 1997; Bienz and Clevers, 2000;
Polakis, 2000). b-Catenin, originally described to function in
epithelial cell–cell adhesion, is implicated also in the Wnt
signalling cascade as a transcriptional activator. In the absence
of Wnt signals, b-catenin is located at the plasma membrane,
linked to E-cadherin, and functions in cell–cell adhesion. Excess
cytoplasmic b-catenin is sequestered in a protein complex
comprised of adenomatous polyposis coli (APC), glycogen
synthase kinase 3b (GSK-3b) and AXIN1 or AXIN2. In this
complex, b-catenin is phosphorylated by GSK-3b and then
targeted by b-transducin repeat-containing protein (b-TrCP) to Received 28 August 2003; accepted 23 November 2003
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sproteasomal degradation. Activated Wnt signalling inhibits the
phosphorylation of b-catenin, thereby preventing its degradation.
The impaired b-catenin degradation leads to an increase in
cytoplasmic b-catenin and its translocation to the nucleus. Nuclear
b-catenin forms heterodimers with members of the T-cell factor
(TCF) family of transcription factors and activates genes contain-
ing TCP-binding sites (Bienz and Clevers, 2000; Polakis, 2000).
It has been demonstrated that b-catenin/TCF-activated gene
transcription can induce neoplastic transformation (Aoki et al,
1999; Kolligs et al, 2002; Miyoshi et al, 2002), and the b-catenin/
TCF target genes comprise the oncogenes c-myc (He et al, 1998),
cyclin D1 (Tetsu & McCormick, 1999) and ITF-2 (Kolligs et al,
2002). Impaired degradation of b-catenin in tumours has been
reported to be caused by inactivating mutations in APC, AXIN1,
AXIN2 or b-TrCP or oncogenic mutations in b-catenin exon 3
(Kinzler and Vogelstein, 1996; Bienz and Clevers, 2000; Liu et al,
2000; Polakis, 2000; Satoh et al, 2000b; Gerstein et al, 2002; Hajra
and Fearon, 2002; Taniguchi et al, 2002; Yokota et al, 2002). These
mutations are in most cases mutually exclusive (Sparks et al, 1998;
Huang et al, 2000; Gayet et al, 2001; Gerstein et al, 2002; Taniguchi
et al, 2002; Yokota et al, 2002).
Several studies have reported nuclear b-catenin expression in up
to 60% of GEJ adenocarcinomas (Bailey et al, 1998; Washington
et al, 1998; Bian et al, 2000; Wijnhoven et al, 2000b; Osterheld et al,
2002). This nuclear expression of b-catenin can be regarded as an
indication for activated, oncogenic, b-catenin/TCF transcription.
However, mutation analysis of APC and b-catenin in GEJ
adenocarcinomas revealed mutations in only less than 7 and 3%
of cases respectively (Powell et al, 1994; Gonzalez et al, 1997; Bian
et al, 2000; Choi et al, 2000). In accordance with these data, we
recently did not find b-catenin exon 3 mutations in a series of 69
GEJ adenocarcinomas (Wijnhoven et al, 2000b). Inactivation of the
AXIN1 gene has been demonstrated to induce b-catenin/TCF
transcription, and AXIN1 gene mutations have been described in
hepatocellular carcinomas, hepatoblastomas, colorectal cancers,
ovarian endometrioid adenocarcinomas and in sporadic medullo-
blastomas (Satoh et al, 2000b; Webster et al, 2000a; Laurent-Puig
et al, 2001; Dahmen et al, 2001b; Wu et al, 2001; Shimizu et al,
2002; Taniguchi et al, 2002; Yokota et al, 2002; Baeza et al, 2003;
Miao et al, 2003). In addition, reduced protein expression of
AXIN1 has recently been reported to correlate with tumour
progression in oesophageal squamous cell carcinoma (Nakajima
et al, 2003). These results prompted us to search for genomic
aberrations in the AXIN1 gene in GEJ adenocarcinomas. From the
previously investigated series of 69 GEJ adenocarcinomas, 17
tumours with prominent nuclear b-catenin expression were
selected for mutation and loss of heterozygosity (LOH) analysis.
The entire coding region including the exon–intron boundaries of
the AXIN1 gene was analysed for genetic alterations by single
strand conformation polymorphism (SSCP) analysis. The presence
of six intragenic single nucleotide polymorphisms (SNPs) was
used to detect LOH. These six SNPs were also used to perform
AXIN1 gene LOH analysis in 20 tumours with strong membranous
b-catenin expression. In addition, AXIN1 protein expression was
investigated by immunohistochemistry in all 37 tumour samples.
MATERIALS AND METHODS
TCF/b-catenin reporter gene assay
All cell lines, JROECL19, JROEL33, SKGT-4, TE-7, OACP4C and
SW480, were cultured in RPMI 1640 supplemented with 10% fetal
calf serum and antibiotics. Transcriptional activation mediated by
TCF/b-catenin protein complexes was determined by transient
transfection of the cell lines with either the pTOPGLOW or
pFOPGLOW reporter constructs as described previously (van de
Wetering et al, 2001). The pTOPGLOW and pFOPGLOW
constructs contain a multimerized wild-type or mutant TCF
binding motive, respectively, upstream of a luciferase gene. Cells
were grown to 50–80% confluency in six-well plates and
transfection was performed with 1mg of purified constructs each,
using Fugene-6 (Boehringer, Mannheim, Germany). Transfection
efficiencies were determined by cotransfection of a pRL-TK
reporter construct (Promega, Madison, WI, USA) that contained
the Renilla luciferase gene under control of the herpes simplex
virus thymidine kinase promoter. Cells were harvested 24h after
transfection. Activity of both luciferases was measured sequentially
in each sample using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI, USA). TCF-mediated gene transcription
was defined by the ratio of pTOPGLOW to pFOPGLOW luciferase
activities. The luciferase activity of the internal control reporter
was used to correct for differences in transfection efficiency.
Tumour and cell line DNA samples
In a previous study of 69 GEJ adenocarcinoma samples consisting
of 54 primary tumours, four lymph node metastases, nine
xenografts and two in vitro cell lines were investigated for b-
catenin expression and b-catenin exon 3 mutations (Wijnhoven
et al, 2000b). From all cases, tumour and normal DNA was isolated
from frozen samples by standard proteinase K digestion and
phenol/chloroform extraction. After b-catenin immunohistochem-
istry on 5mm paraffin sections, parts of the tumour with intense
nuclear reactivity were isolated by microdissection from con-
secutive unstained sections. From the microdissected fragments,
DNA was isolated with standard proteinase K digestion followed
by phenol/chloroform extraction and ethanol precipitation. No
b-catenin exon 3 aberrations were found in these samples. For
the present study, the DNA from 17 tumours with strong nuclear
b-catenin expression was used. Fifteen samples were originated
from primary GEJ adenocarcinomas and two were from GEJ
adenocarcinoma-derived cell lines JROECL19 and JROECL33
(Rockett et al, 1997). In addition, the DNAs from 20 tumours
with strong membranous b-catenin expression were investigated
for LOH with the six SNPs. These 20 samples comprised 17
primary tumours and the established cell lines OACP4C, SKGT-4
and TE-7 (Altorki et al, 1993; Nishihira et al, 1993; de Both et al,
2001). Cell lines JROECL19 and 33 were obtained from the
European Collection of Cell Cultures (ECACC, Wiltshire, UK),
SKGT-4 and TE-7 were kind gifts from D Schrump, NIH, Bethesda,
USA and T Kudo, Tohoku University, Sendai, Japan, respectively;
OACP4C was established at our own institute. From cell lines
JROECL19 and JROECL33, patient’s normal tissue was kindly
provided by Dr SJ Darnton, Birmingham Heartlands Hospital,
Birmingham, UK. From cell line OACP4C patient’s normal tissue
was obtained from our pathology archive, and from cell lines
SKGT-4 and TE-7 patient’s normal tissue was not available. To
determine SNP frequencies in the normal population, we used
DNA isolated from 161 healthy Caucasian blood donor volunteers.
Mutation analysis of the AXIN1 gene
The 17 pairs of tumour and normal DNA from tumours with
nuclear b-catenin expression were screened for aberrations in the
AXIN1 gene. The entire coding sequence, including the exon–
intron boundaries, was investigated by PCR-SSCP using the
previously described 23 sets of primers with slight modifications
(Lin et al, 2000). All amplifications were performed in 15ml PCR
containing 50–100ng DNA, 1.5mM MgCl2, 0.02mM dATP, 0.2mM
dGTP, dCTP and dTTP each, 0.8mCi of [
32P]dATP (Amersham
Biosciences, Buckinghamshire, UK), 20pmol of each primer and
0.3U AmpliTaq Gold polymerase (Perkin-Elmer Applied Biosys-
tems, Foster City, CA, USA). AmpliTaq Gold polymerase was
used because this enzyme is superior to other DNA polymerases
with regard to amplification of DNA retrieved from routine
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sformalin-fixed and paraffin-embedded tissues. To the PCRs with
primer sets 4, 10, 12, 13, 14, 15, 18, 21 and 23, DMSO (5%) was added
to increase the amplification efficiency. The PCRs were performed
with a hotstart of 951C for 5min followed by 35 cycles of 951Cf o r
30s, 551C (primer sets 10 and 14 at 58 and 601C, respectively) for
45s and 721C for 45s and ended up with an extension step of 721C
for 10min. The PCR products were diluted 1:4 with loading buffer
(95% formamide, 10mM EDTA, 0.05% bromophenol blue and 0.05%
xylene cyanol), heated for 5min, cooled on ice and electrophoresed
in 6% polyacrylamide gels containing 10% glycerol at 7 W overnight
at room temperature, in 1 TBE running buffer. Gels were dried and
exposed to X-ray films at  801C. Results were evaluated by visual
inspection. With the used SSCP conditions, the PCR products from
primer sets 18, 19 and 21 resulted in simple banding patterns,
inefficient for the detection of aberrations. To increase the DNA
aberration detection efficiency, these PCR products were electro-
phoresed without glycerol at 41C for 6h resulting in more complex
banding patterns. For each variant SSCP pattern identified by SSCP
analysis, the genomic DNA samples were reamplified for bidirec-
tional direct sequencing with the amplification primers. In 20 DNA
samples from tumours with strong membranous b-catenin expres-
sion, LOH was determined by SSCP analysis of six detected SNPs.
These SNPs are at positions (according to GenBank accession no.
AF009674) A94C, C874T, intron 4þ17 G-A (nucleotide position
identified from exon–intron boundary), G1396A, T1942C and
G2063A. Amplification of these SNPs was performed with primer
sets 1, 7, 11, 12 and 17, respectively.
b-Catenin and AXIN1 immunohistochemistry
In all 37 tumour samples, immunostaining for b-catenin and AXIN1
was performed on 5mm paraffin sections with a mouse anti-human
b-catenin monoclonal antibody (Transduction Laboratories, Lex-
ington, KY, USA; 1:200, 30min, room temperature) (Wijnhoven
et al, 2000b) and a rabbit polyclonal anti-human AXIN1 antibody
(Zymed Laboratories, San Francisco, CA, USA; 1:25, 30min, room
temperature), respectively. After deparaffinisation and treatment
with methanol/H2O2, antigen retrieval was performed in citrate
buffer for 15min prior to incubation with the b-catenin antibody.
No antigen retrieval was necessary for the AXIN1 immunohisto-
chemistry. Immunoreactivity was made visible by a standard avidin
biotin immunoperoxidase technique, using a commercially available
kit (Labvision, Fremont, CA, USA) and diaminobenzidine hydro-
chloride (Fluka, Neu-Ulm, Germany). As negative controls, normal
mouse immunoglobulins and normal rabbit serum were used.
RESULTS
TCF/b-catenin reporter gene assay
The TCF/b-catenin reporter gene assay was performed with the
pTOPGLOW and pFOPGLOW constructs. Cell lines JROECL19 and
JROECL33, both with nuclear b-catenin expression (JROECL19,
Figure 1C), showed 350- and 18-fold increase in transcriptional
activity of the pTOPGLOW reporter as compared to the negative
control pFOPGLOW (Figure 2). Cell lines SKGT-4, TE-7 and
OACP4C, all with membranous b-catenin immunoreactivity (TE-7,
Figure 1D), showed no enhanced transcription of the pTOPGLOW
reporter (Figure 2).
Mutation analysis of the AXIN1 gene
SSCP analysis of the AXIN1 gene in 17 tumour/normal DNA pairs
from tumours with strong nuclear b-catenin expression (Figure
1A, C) revealed six different aberration patterns. All these
aberrations were also present in the corresponding normal DNA.
Sequencing of the aberrant samples identified six different SNPs.
These were at positions (according to GenBank accession no.
AF009674) A94C, C874T, intron 4þ17 G-A, G1396A, T1942C
and G2063A (Figure 3).
Figure 1 Immunohistochemistry of b-catenin in GEJ adenocarcinomas and cell lines (b-catenin antibody, DAB and haematoxylin counterstain,
magnification  400). (A) GEJ adenocarcinoma. Strong nuclear expression of b-catenin in the tumour cells. (B) GEJ adenocarcinoma. Prominent
membranous expression of b-catenin. (C) Cell line JROECL19. Strong nuclear expression of b-catenin. (D) Cell line TE-7. Membranous expression of b-
catenin.
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sOf the 17 cases, 15 appeared to be heterozygous for at least one
polymorphism and LOH was observed in 11 (73%) cases (Table 1).
The polymorphisms were used to investigate LOH in 20 GEJ
adenocarcinoma cases with strong membranous b-catenin expression
(Figure 1B, D). Also in this series, all six polymorphisms were present
and in 10 of 13 (77%) informative cases LOH was found (Table 2).
The T1942C and G2063A SNPs were found to have population
frequencies of 21 and 3%, respectively (Tables 1 and 2). The
relatively frequent SNP T1942C was only described very recently
in two independent studies (Baeza et al, 2003; Miao et al,2 0 0 3 )
and remained undetected in 10 AXIN1 gene mutation studies (Lin
et al, 2000; Satoh et al, 2000a; Webster et al,2 0 0 0 b ;D a h m e net al,
2001a; Wu et al, 2001; Miao et al,2 0 0 2 ;S h i m i z uet al, 2002;
Taniguchi et al, 2002; Yokota et al, 2002; Nakajima et al,2 0 0 3 ) .I n
most of these studies, as in ours, SSCP analyses were used. To
determine whether the SSCP conditions have influence on the
detection of the T1942C SNP, we amplified DNA samples with
AmpliTaq Gold and with Promega Taq DNA polymerases (Promega,
Madison, WI, USA) in both AmpliTaq Gold and Promega Taq
buffers. The AmpliTaq Gold buffer consists of 15mM Tris-HCl (pH
8.0), 50mM KCl and 1.5mM MgCl2 and the Promega buffer consists
of 10mM Tris–HCl (pH 9.0), 50mM KCl, 1.5mM MgCl2 and 0.1%
Triton X-100. As demonstrated in Figure 4, the T1942C SNP is only
clearly visible after amplification with the AmpliTaq buffer.
b-Catenin and AXIN1 immunohistochemistry
As mentioned before, 37 GEJ adenocarcinoma samples were
investigated, 17 with strong nuclear b-catenin expression and 20
cases with normal membranous reactivity (Figure 1). Eleven of the
OACP4C
TE-7
SKGT-4
JROECL33
JROECL19
SW480
0 50 100 150 200 250 300 350 400 450
TCF-mediated transactivation
Figure 2 TCF-mediated transcriptional activation in GEJ adenocarcino-
ma cell lines. Constitutive transcriptional activation was detected in cell lines
JROECL33 and JROECL19. APC mutant colorectal cancer cell line SW480
served as a positive control. TCF-mediated transcriptional activity was
defined as the ratio of pTOPGLOW:pFOPGLOW luciferase activities,
each corrected for pRL-TK luciferase activities and where no transactivation
equals 1.
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Figure 3 PCR-SSCP and sequencing analyses of the SNPs in tumours
(T) and corresponding normal DNA (N), compared with DNA from
individuals without SNPs (N1). Informative cases with LOH are shown.
Black arrows point to allelic patterns. Red arrow heads point to deleted
alleles in the tumour DNA. The sequencing chromatograms below each
autoradiograph show the alterations (note the substituted nucleotide
marked by an asterisk), which all represent SNPs. SNPs A94C and G1396A
are annotated in the reverse complementary direction, whereas the SNPs
C874T, intron 4þ17 G-A, T1942C and G2063A are annotated in the
forward direction.
Table 1 Patterns of allelic loss in GEJ adenocarcinomas with nuclear -catenin expression
Case A94C C874T Intron 4+17 G-A G1396A T1942C G2063A
1 Loss HN Loss HN HN HN
2 HN No loss HN No loss Loss HN
3H N H N H N H N H N H N
4 HP HN Loss HN HN HN
5 Loss HN HN HN HN HN
6 HN HP HN No loss HN HN
7 HN HP HN No loss HN HN
8 Loss HN Loss No loss No loss HN
9 HN Loss HN HN HN HN
10 No loss HN No loss No loss HN HN
11 HN HN HN HN HN HN
12 HN HN HN HN HN HN
13 HN HN HN Loss Loss HN
14 HN HN HN Loss HN HN
15 HN Loss HN Loss HN HN
Frequency 6/34 (18%) 8/34 (24%) 4/34 (12%) 9/34 (26%) 4/34 (12%) 1/34 (3%)
Frequency NP ND ND ND ND 69/322 (21%) 9/322 (3%)
HN¼homozygous normal; HP¼homozygous polymorphism; NP¼normal population; ND¼no data.
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s15 (73%) informative cases with nuclear b-catenin expression and
10 of 13 (77%) informative cases with membranous b-catenin
immunoreactivity showed loss of the AXIN1 gene locus. In all
tumour samples AXIN1 protein expression was confined to the
cytoplasm of the tumour cells exclusively (Figure 5). No consistent
differences in AXIN1 protein expression were observed between
tumours with and without AXIN1 locus loss, irrespective of nuclear
or membranous b-catenin expression (Figure 5).
DISCUSSION
Nuclear b-catenin expression has been reported in up to 60%
of GEJ adenocarcinomas (Bailey et al, 1998; Washington et al,
1998; Bian et al, 2000; Wijnhoven et al, 2000b; Osterheld et al,
2002). In the present study, we used the nuclear expression of b-
catenin in GEJ adenocarcinomas as an indication for activated Wnt
signalling. This presupposition is substantiated by our finding of
highly enhanced TCF-mediated transcriptional activity in the cell
lines JROECL19 and JROECL33, both with nuclear b-catenin
expression. None of the three cell lines without nuclear but with
membranous b-catenin expression had increased transcription of
the TOPGLOW reporter. Activated Wnt signalling in tumours is
caused by increased levels of b-catenin, which can be the result of
mutations in APC, b-catenin, AXIN1, AXIN2 or b-TrCP (Kinzler
and Vogelstein, 1996; Bienz and Clevers, 2000; Liu et al, 2000;
Polakis, 2000; Satoh et al, 2000b; Gerstein et al, 2002; Hajra
and Fearon, 2002; Taniguchi et al, 2002; Yokota et al, 2002). To
date only APC and b-catenin mutation analysis in GEJ adeno-
carcinomas has been performed and only few mutations were
found (Powell et al, 1994; Gonzalez et al, 1997; Bian et al, 2000;
Choi et al, 2000; Wijnhoven et al, 2000b). Therefore, the
mechanism of Wnt activation remains obscure in these tumours.
These results prompted us to investigate GEJ adenocarcinoma
samples with nuclear b-catenin expression for mutations in the
AXIN1 gene. None of the tumours in the present study showed
b-catenin exon 3 mutations (Wijnhoven et al, 2000b). In 17 GEJ
adenocarcinoma samples, no AXIN1 gene mutations were found.
We therefore conclude that Wnt activation in GEJ tumours is not
caused by AXIN1 gene mutations.
Six previously described polymorphisms in the AXIN1 gene
were detected. All the detected DNA variations were also found in
patients’ constitutional DNAs indicating that they are truly
polymorphisms and not somatic mutations. The G2063A SNP in
exon 6 results in a substitution from glycine to serine. This
polymorphism is described by Webster et al (2000a), although
these authors annotated the polymorphism to exon 7 and regarded
Table 2 Patterns of allelic loss in GEJ adenocarcinomas without nuclear -catenin expression
Case A94C C874T Intron 4+17 G-A G1396A T1942C G2063A
1 No loss HP Loss HN Loss HN
2 HN Loss HN HN Loss HN
3 HN HN HN Loss Loss HN
4 HN HN HN HN Loss HN
5 HN HP HN HN Loss HN
6 HN HP HN Loss HN Loss
7 HN No loss HN HN HN HN
8 No loss HP No loss HN HN HN
9H N H N H N H N H N H N
10 HN HN HN HN HN HN
11 Loss HP Loss HN HN HN
12 Loss Loss HN Loss Loss HN
13 HN HP HN HN HP HN
14 HN HN HN HN HN HN
15 HP HP HP HN HN HN
16 No loss HP No loss HN No loss HN
17 HN Loss HN HN HN HN
Frequency 7/40 (18%) 20/40 (50%) 6/40 (15%) 5/40 (13%) 9/40 (23%) 2/40 (5%)
Frequency NP ND ND ND ND 69/322 (21%) 9/322 (3%)
For abbreviations see Table 1 footnote.
T/T C/CT/C T/T C/CT/C T/T C/CT/C
AB C
Figure 4 T1942C PCR-SSCP. Three DNA samples, 1942T/T (homo-
zygous normal), 1942C/C (homozygous polymorphic), 1942T/C (hetero-
zygous), were amplified with AmpliTaq Gold polymerase and AmpliTaq
Gold buffer (A), Promega Taq and Promega buffer (B), Promega Taq and
AmpliTaq Gold buffer (C) and with AmpliTaq Gold and Promega buffer
(no PCR products obtained). All samples were amplified and SSCP-
electrophoresed in the same experiment. Arrows point to the polymorphic
SSCP fragment. Note that the polymorphic fragments are clearly visible
only after amplification in AmpliTaq Gold buffer (A, C).
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sit as a silent polymorphism. Furthermore, in a recent study by
Taniguchi et al (2002), the G2063A polymorphism is found in one
hepatocellular carcinoma and in one hepatoblastoma. Patients’
normal tissues were not investigated and because the SNP was not
found in their 147 control individuals, they regarded it as an
AXIN1 mutation. We found a G2063A allele frequency of 4 and 3%
in GEJ adenocarcinoma patients and healthy controls, respectively,
indicating that this AXIN1 gene variant is an SNP and not a
mutation. In addition, we found a silent T1942C SNP (ala-ala) in
exon 6 with an allele frequency of 18 and 21% in GEJ
adenocarcinoma patients and healthy controls, respectively. This
frequent SNP was only recently described, with comparable allele
frequencies, in two independent studies (Baeza et al, 2003; Miao
et al, 2003) and remained undetected in 10 AXIN1 gene mutation
investigations within total 670 DNA samples (Lin et al, 2000; Satoh
et al, 2000b; Webster et al, 2000b; Dahmen et al, 2001a; Wu et al,
2001; Miao et al, 2002; Shimizu et al, 2002; Taniguchi et al, 2002;
Yokota et al, 2002; Nakajima et al, 2003). We demonstrate that
detection of the T1942C SNP by SSCP analysis is influenced by the
PCR buffer characteristics. This finding suggests that also other
SSCP parameters (gel composition, running buffer, running
temperature, etc) can have influence on the SNP detection.
The AXIN1 gene polymorphisms were used to determine LOH.
Fifteen of 17 cases with nuclear b-catenin expression appeared to
be heterozygous for at least one polymorphism, and from these in
11 (73%) clear LOH was observed. This frequent loss of the AXIN1
gene could point to a dosage effect where the presence of 50% of
the AXIN1 protein is insufficient for proper b-catenin degradation
and subsequently leads to Wnt activation. To gather more
information about this possibility, we investigated AXIN1 gene
LOH with the detected SNPs in a series of 20 tumours from our
previous study with strong, normal membranous b-catenin
expression. These included three cell lines (OACP4C, SKGT-4
and TE-7) without enhanced TCF-mediated transcriptional activ-
ity. In this series, the T1942C and G2063A SNPs were detected in
four and two samples, respectively. A total of 13 cases were
informative and in 10 (77%) clear LOH was observed.
By AXIN1 immunohistochemistry, no differences were observed
between tumours with and without AXIN1 locus loss. It is known
that with the semiquantitative immunohistochemical method a
two-fold reduction in protein expression cannot be detected. In
oesophageal squamous cell carcinoma, reduced protein and RNA
expression has recently been described by Nakajima et al (2003).
These investigators suggest AXIN1 gene silencing by promotor
methylation, in addition to allelic losses, as a mechanism
for AXIN1 downregulation. Our immunohistochemical results
indicate that AXIN1 gene silencing does not occur in GEJ
adenocarcinomas.
All the above-mentioned results indicate that AXIN1 gene haplo-
insufficiency is not sufficient for Wnt activation. This is in
accordance with studies that demonstrated biallelic inactivation of
the AXIN1 gene in several tumour types (Satoh et al, 2000b;
Laurent-Puig et al, 2001; Taniguchi et al, 2002; Yokota et al, 2002),
although heterozygous AXIN1 gene inactivation has also been
described (Dahmen et al, 2001b; Webster et al, 2000a). Chromo-
some 16p loss has been reported in up to 40% in GEJ
adenocarcinomas (Gleeson et al, 1998) and the presence of a
tumour suppressor gene on 16p13.3 has been suggested by
Takamochi et al (2001). The frequent AXIN1 locus LOH in our
study could point to a gene dosage effect independent of Wnt
pathway activation. Furthermore, it cannot be excluded that an as
yet to be defined tumour suppressor gene on 16p13.3 is the actual
target for LOH in GEJ adenocarcinomas.
Since mutations in APC, b-catenin and AXIN1 do not play a
major role in the frequent TCF/b-catenin activation in GEJ
adenocarcinomas, other components should be considered. AXIN2
gene mutations have been described in 11 colorectal cancers (Liu
et al, 2000), one endometrioid ovarian adenocarcinoma (Wu et al,
2001) and two hepatocellular carcinomas (Taniguchi et al, 2002).
Of these 14 tumour samples, 12 had nuclear b-catenin expression
Figure 5 Immunohistochemistry of AXIN1 in GEJ adenocarcinomas (AXIN1 antibody, DAB and haematoxylin counterstain, magnification  200). (A, B)
GEJ adenocarcinomas with nuclear b-catenin expression without (A) and with (B) AXIN1 locus LOH. (C, D) GEJ adenocarcinomas with membranous b-
catenin expression without (C) and with (D) AXIN1 locus LOH. Note the strong cytoplasmic AXIN1 expression in the tumour cells in all four cases.
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appear to be present exclusively in tumours with a microsatellite
instable phenotype since all AXIN2 mutant colorectal carcinomas
and the ovarian endometrioid adencarcinoma were microsatellite
instable (Wu et al, 2001; Taniguchi et al, 2002). The AXIN2 gene is
an improbable candidate for Wnt activation in GEJ adenocarci-
nomas because microsatellite instability has been described in only
less than 6% in these tumours (Gleeson et al, 1996; Wijnhoven et al,
2000b). Another candidate is b-TrCP, involved in b-catenin
degradation. Recently, b-TrCP mutations have been described in
two prostate cancer samples, of which one had nuclear b-catenin
expression (Gerstein et al, 2002).
Activated Wnt signalling can also be the result of activation of
the canonical Wnt pathway by secreted Wnts or by expression of
the Wnt receptors frizzled (Tanaka et al, 1998; Mizushima et al,
2002). In cell line cultures, this would imply the presence of an
autocrine Wnt/frizzled loop. Furthermore, tumour necrosis factor-
a has recently been demonstrated to induce TCF/b-catenin-
mediated transcription in a GEJ adenocarcinoma cell line (Tselepis
et al, 2002). These findings indicate that next to mutational
activation of the Wnt pathway, gene expression alterations should
be considered also as driving force behind Wnt activation in GEJ
adenocarcinomas.
In summary, our results demonstrate that nuclear b-catenin
expression in GEJ adenocarcinoma cell lines correlates with TCF-
mediated transcription activation and so with activated Wnt
signalling. The frequent nuclear localisation of b-catenin in GEJ
adenocarcinomas cannot be attributed by AXIN1 gene mutations.
The mechanism of Wnt activation in these tumours remains to be
established. In addition, the role of the frequent LOH of the AXIN1
locus in GEJ adenocarcinomas deserves further investigation.
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